BrightSpring Health Services Projects Strong 2026 Growth

BrightSpring Health Services, Inc. ((BTSG)) has held its Q4 earnings call. Read on for the main highlights of the call.

BrightSpring Health Services struck an upbeat tone on its latest earnings call, pairing standout 2025 growth with confident 2026 guidance despite visible policy and customer headwinds. Management emphasized double‑digit gains in revenue and EBITDA, stronger cash generation, and lower leverage, arguing that scale, quality metrics, and strategic portfolio moves leave the company well positioned for the next leg of expansion.

Robust 2025 Revenue and EBITDA Performance

BrightSpring posted 2025 revenue of $12.9 billion, up 28% year over year, with adjusted EBITDA climbing 34% to $618 million as scale and mix shifts drove operating leverage. The fourth quarter was even stronger, with revenue growing about 29% and adjusted EBITDA surging roughly 41% versus the prior‑year period.

Pharmacy Solutions Drives the Growth Engine

Pharmacy Solutions remained the core growth engine, delivering $11.4 billion of revenue in 2025, a 31% increase from a year earlier. In the fourth quarter, pharmacy revenue rose 32% while segment adjusted EBITDA jumped 44%, backed by 43% specialty and infusion revenue growth and 10.8 million total scripts.

Provider Services Adds Steady Expansion and Margin Gains

Provider Services contributed $1.5 billion of 2025 revenue, up 11% year over year, showcasing a steadier but profitable growth profile. Fourth‑quarter provider revenue advanced 13%, segment EBITDA grew 16%, and margins improved to 16.4%, helped by home health revenue rising 19% and census reaching about 35,000.

Cash Generation Strengthens Balance Sheet and Lowers Leverage

Operating cash flow reached $490 million for 2025, including $232 million in the fourth quarter, reinforcing the quality of earnings and giving the company financial flexibility. Net debt stood at $2.5 billion at year‑end, with leverage reduced to 2.99x and expected to move toward roughly 2.6x after the Community Living sale.

Strategic Deals Reshape Portfolio and Capital Allocation

BrightSpring continued to reshape its portfolio, buying 107 Amedisys branches for $239 million in cash, which generated about $345 million of 2025 pro forma revenue. The company expects around $30 million of 2026 adjusted EBITDA from Amedisys and LHC combined while planning to use roughly $715 million of Community Living sale proceeds primarily for debt reduction.

Quality Metrics Underpin Growth in Care Delivery

Management highlighted broad‑based operational gains, with company‑wide adjusted EBITDA margin expanding to 4.8% in 2025, up 20 basis points year over year. Home health quality scores remained strong, hospice satisfaction ranked in the top tier, and pharmacy operations delivered near‑perfect accuracy and high on‑time delivery, supporting retention and payer relationships.

Pipeline and Structural Growth Drivers Remain Intact

The limited distribution drug portfolio grew to 149 products, including 24 launches in 2025 and five in the fourth quarter, reinforcing BrightSpring’s positioning in higher‑value specialty categories. Management cited future growth from additional LDD launches, rising generic utilization, fee‑for‑service expansion, better commercial execution, and continued infusion build‑out.

IRA and Generics Create Material Revenue Headwinds

Despite strong growth, the company faces sizable policy and mix pressures, including about $200 million of Inflation Reduction Act impact in specialty and infusion. When combined with brand‑to‑generic conversions, specialty and infusion headwinds rise to a little over $400 million, alongside roughly $175 million of IRA impact in home and community pharmacy.

Customer Bankruptcy Weighs on Home and Community Volumes

Home and community pharmacy volumes dipped about 1% in the quarter as BrightSpring unwound a large bankrupt customer and exited uneconomic contracts. Management expects script pressure in this channel to persist until roughly the third quarter of 2026 as the company works through prior‑year comparisons and rebases the book.

Integration Investment Dilutes Near‑Term Margins on Amedisys

The newly acquired Amedisys branches currently carry lower margins, described as roughly high single‑digit on a pro forma basis, and will require integration and technology spending. Leadership cautioned that these transition costs mean margin accretion will be gradual, with the timing to reach company‑average profitability still uncertain.

Complex Pharmacy Headwinds Add Guidance Sensitivity

Management underscored that multiple moving parts—IRA effects, generic conversions, customer transitions, and payer negotiations—make the 2026 pharmacy revenue cadence harder to predict. While BrightSpring flagged gross headwinds and various offsets, including improved dispensing fees and operational savings, the net impact on results remains somewhat fluid.

Short‑Term Script Pressure and Seasonal Softness

The company anticipates continued year‑over‑year script challenges in home and community pharmacy until about the third quarter as it laps the customer unwind. Early 2026 results will also feel typical seasonal pressure, with the first quarter being a shorter period and usually the lowest by days and volume.

Guidance Signals Confidence in Double‑Digit Growth Ahead

For 2026, BrightSpring guided to $14.45 billion to $15.0 billion in revenue from continuing operations, implying around 12% to 16% growth and about 14% at the midpoint. Adjusted EBITDA is forecast between $760 million and $790 million, around 23% to 28% growth, with expected sequential improvement through the year, expanding margins, new LDD launches, and home and community scripts normalizing by roughly the third quarter.

BrightSpring’s earnings call painted a picture of a company balancing strong growth and quality metrics against policy‑driven and customer‑specific headwinds. Investors weighing the story will see a business leaning on scale, specialty pharmacy, and disciplined capital deployment to drive double‑digit gains, with near‑term noise but a clearer path to higher margins and lower leverage over time.